Summary by Futu AI
On August 5, 2024, Haplopharma Holdings Limited (Haplopharma-B) submitted the latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited, covering the situation as of July 31, 2024. The report shows that the company's statutory/registered capital and issued shares (excluding treasury shares) remained unchanged at 20,000,000,000 shares with a face value of $0.000025 per share, and the total capital and issued shares of the statutory/registered capital were $500,000 and 768,876,410 shares, respectively. In addition, the number of share options held in the company's share option plan at the end of this month was 33,185,100, a decrease of 321,000 from the previous month, and the number of new shares issued due to the exercising of share options was 0. The report also confirms that all issuances or transfers of securities or treasury shares have been formally authorized and approved by the board of directors, and comply with all applicable listing rules, laws, and other regulatory requirements.
